Invizyne Technologies (NASDAQ:IZTC) Shares Down 0.5% - Time to Sell?

Key Points

• Invizyne Technologies Inc. (NASDAQ:IZTC) shares experienced a slight decline of 0.5% on Thursday, trading as low as $14.01 before closing at $14.43.
• Trading volume was significantly lower than average, with approximately 3,961 shares exchanged, marking an 89% decrease from the daily average.
• BNP Paribas Financial Markets acquired a new position in the company, purchasing 2,113 shares valued at about $35,000 in the fourth quarter.

Invizyne Technologies Inc. (NASDAQ:IZTC - ) shares dropped 0.5% on Thursday . The company traded as low as $14.01 and last traded at $14.43. Approximately 3,961 shares traded hands during trading, a decline of 89% from the average daily volume of 37,647 shares. The stock had previously closed at $14.50.

Invizyne Technologies Trading Down 0.5%

The stock's fifty day moving average is $11.22 and its two-hundred day moving average is $11.63.

Hedge Funds Weigh In On Invizyne Technologies

An institutional investor recently bought a new position in Invizyne Technologies stock. BNP Paribas Financial Markets acquired a new position in shares of Invizyne Technologies Inc. (NASDAQ:IZTC - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,113 shares of the company's stock, valued at approximately $35,000.

Invizyne Technologies Company Profile

Invizyne Technologies Inc is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc is based in Monrovia, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.